Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Other Operating Expenses (2022 - 2025)

Atara Biotherapeutics' Other Operating Expenses history spans 4 years, with the latest figure at $104000.0 for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 98.47% year-over-year to $104000.0; the TTM value through Dec 2025 reached $21.2 million, up 0.97%, while the annual FY2025 figure was $21.2 million, 0.97% up from the prior year.
  • Other Operating Expenses reached $104000.0 in Q4 2025 per ATRA's latest filing, down from $115000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $50.2 million in Q2 2022 to a low of $104000.0 in Q4 2025.
  • Average Other Operating Expenses over 4 years is $9.3 million, with a median of $3.3 million recorded in 2024.
  • The largest YoY upside for Other Operating Expenses was 929.67% in 2025 against a maximum downside of 98.49% in 2025.
  • A 4-year view of Other Operating Expenses shows it stood at $50.2 million in 2022, then tumbled by 99.57% to $216000.0 in 2023, then skyrocketed by 3045.83% to $6.8 million in 2024, then tumbled by 98.47% to $104000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Other Operating Expenses are $104000.0 (Q4 2025), $115000.0 (Q3 2025), and $554000.0 (Q2 2025).